CVM
CEL-SCI Corporation AMEX Listed Dec 8, 1983$1.11
+13.92%
vs $0.97
Mkt Cap $4.5M
52w Low $0.97
1.1% of range
52w High $13.04
50d MA $1.86
200d MA $5.13
P/E (TTM)
—
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.6x
ROE
-213.7%
P/FCF
-0.0x
RSI (14)
32.70
ATR (14)
$0.11
Beta
1.00
50d MA
$1.86
200d MA
$5.13
Avg Volume
495.0K
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
8229 Boone Boulevard · Vienna, VA 22182 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | — | -0.68 | — | 4.78 | +1.0% | +8.4% | -6.6% | -0.8% | -7.3% | +2.9% | — |
| Jan 12, 2026 | AMC | — | -2.70 | — | 5.13 | -0.2% | -1.0% | +3.7% | -5.3% | +3.2% | +1.9% | — |
| Aug 14, 2025 | AMC | — | -1.36 | — | 8.14 | -0.4% | +6.9% | +2.5% | -5.0% | +5.1% | +3.0% | — |
| May 14, 2025 | AMC | — | -2.40 | — | 8.64 | +4.2% | -4.2% | -4.3% | -9.1% | -14.9% | -11.7% | — |
| Feb 14, 2025 | AMC | — | -3.30 | — | 15.12 | +0.0% | +7.1% | +13.3% | -17.6% | -4.8% | -2.5% | — |
| Jan 13, 2025 | AMC | -3.00 | -2.70 | +10.0% | 14.76 | -2.4% | -2.4% | +2.5% | -2.4% | +0.0% | -2.5% | — |
| Aug 14, 2024 | AMC | -3.60 | -4.20 | -16.7% | 41.40 | -0.9% | -0.9% | -0.9% | +1.8% | -2.6% | +0.9% | — |
| May 16, 2024 | AMC | -3.90 | -4.20 | -7.7% | 50.40 | +0.7% | -9.3% | -0.8% | +4.0% | -0.8% | -2.3% | — |
| Feb 14, 2024 | AMC | -4.20 | -4.20 | +0.0% | 85.68 | +0.0% | -0.8% | -0.8% | -4.3% | -3.1% | -0.5% | — |
| Dec 22, 2023 | AMC | -4.20 | -4.80 | -14.3% | 99.00 | +0.7% | +11.6% | -2.6% | -5.0% | -4.2% | -1.1% | — |
| Aug 11, 2023 | AMC | -4.50 | -5.71 | -26.9% | 44.64 | +0.0% | +0.0% | +6.5% | -3.0% | -2.3% | +0.0% | — |
| May 12, 2023 | AMC | -0.17 | -5.71 | -3258.8% | 86.40 | +1.2% | +8.3% | +1.5% | +2.3% | -5.6% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 12 | EF Hutton | Maintains | Buy → Buy | — | $86.76 | $86.76 | +0.0% | -1.7% | -1.3% | +9.4% | +11.7% | -23.4% |
| Mar 9 | EF Hutton | Maintains | Buy → Buy | — | $98.64 | $98.64 | +0.0% | -6.2% | -8.2% | +3.4% | +0.8% | -2.4% |
| Dec 29 | EF Hutton | Maintains | Buy → Buy | — | $81.36 | $81.72 | +0.4% | -2.7% | +6.8% | +5.1% | +3.6% | -2.7% |
| Aug 25 | EF Hutton | Maintains | Buy → Buy | — | $153.36 | $155.16 | +1.2% | -1.6% | -6.4% | +1.0% | -1.5% | +1.0% |
| Apr 7 | EF Hutton | Maintains | Buy → Buy | — | $136.44 | $141.48 | +3.7% | -1.6% | +5.1% | -8.9% | -7.8% | +3.6% |
| Jan 13 | H.C. Wainwright | Maintains | Buy → Buy | — | $280.08 | $298.80 | +6.7% | +20.1% | -2.7% | +0.1% | +7.9% | +2.1% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $280.08 | $298.80 | +6.7% | +20.1% | -2.7% | +0.1% | +7.9% | +2.1% |
| Feb 20 | Taglich Brothers | Maintains | Speculative Buy → Buy | — | $2430.00 | $2430.00 | +0.0% | +0.0% | -3.7% | +0.0% | +0.0% | +0.0% |
| Feb 13 | Chardan Capital | Maintains | Buy → Buy | — | $2430.00 | $2430.00 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Jan 14 | Laidlaw & Co. | Maintains | Buy → Buy | — | $2520.00 | $2610.00 | +3.6% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | KERSTEN GEERT RDir/Off | Chief Executive Officer | Buy | 300,000 | $1.20 | $360K | 311,547 | -7.56% | +0.70% |
| May 13, 2026 | KERSTEN GEERT RDir/Off | Chief Executive Officer | Buy | 100,000 | $1.19 | $119K | 222,497 | +10.00% | -8.80% |
8-K · 8.01
!! High
CEL-SCI Corporation -- 8-K 8.01: Material Event / Announcement
CEL-SCI Corporation completed a securities offering in June 2026, though the specific terms and financial impact require review of the attached press releases for investor assessment.
Jun 16
8-K · 1.01
!! High
CEL-SCI Corporation -- 8-K 1.01: Distribution Agreement
May 14
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 243,645 | $782K | New | Mar 2026 |
| 2 | Bank Of America Corp /de/ | 40,997 | $132K | — | Mar 2026 |
| 3 | Renaissance Technologies Llc | 35,890 | $115K | Added | Mar 2026 |
| 4 | Commonwealth Equity Services, Llc | 21,683 | $114K | Reduced | Dec 2025 |
| 5 | Us Bancorp \de\ | 18,413 | $97K | Added | Dec 2025 |
| 6 | Jane Street Group, Llc | 15,707 | $83K | New | Dec 2025 |
| 7 | Northern Trust Corp | 18,934 | $61K | Added | Mar 2026 |
| 8 | Ubs Group Ag | 16,637 | $53K | Added | Mar 2026 |
| 9 | Hightower Advisors, Llc | 10,000 | $53K | New | Dec 2025 |
| 10 | Archer Investment Corp | 1,500 | $5K | — | Mar 2026 |
| 11 | Wells Fargo & Company/mn | 766 | $2K | New | Mar 2026 |
| 12 | Steward Partners Investment Advisory, Llc | 686 | $2K | — | Mar 2026 |
| 13 | Hilton Head Capital Partners, Llc | 450 | $1K | — | Mar 2026 |
| 14 | Morgan Stanley | 118 | $620 | Reduced | Dec 2025 |
| 15 | Advisornet Financial, Inc | 97 | $311 | — | Mar 2026 |
| 16 | Bnp Paribas Financial Markets | 54 | $173 | Added | Mar 2026 |
| 17 | Alerus Financial Na | 38 | $122 | — | Mar 2026 |
| 18 | Gables Capital Management Inc. | 26 | $83 | — | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 7 | $21 | Reduced | Mar 2026 |
| 20 | Royal Bank Of Canada | 62 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 42,802 | $182K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 11,520 | $49K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 11,060 | $47K | Feb 2026 |
| 4 | Ultra-Small Company Market Fund | 7,500 | $24K | Mar 2026 |
Valuation
Market Cap
$4.5M
Enterprise Value
-$6.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.03x
P/B
0.28x
P/S
—
P/FCF
-0.00x
EV/EBITDA
—
Shares Out
4.1M
Financials (TTM)
Revenue
$0
Net Income
-$22.7M
EBITDA
-$18.4M
Free Cash Flow
-$17.16B
Op Cash Flow
-$17.12B
EPS Basic
$-6.27
EPS Diluted
$-3.47
EPS Forward
$-4.16
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$28.2M
Total Liab.
$12.2M
Total Equity
$16.0M
Cash
$11.0M
LT Debt
$0
Book Value/Sh
$3.93
Debt/Equity
0.59x
Current Ratio
2.26
Quick Ratio
2.20
Returns & Growth
ROE
-213.7%
ROA
-104.0%
ROIC
-97.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+53.6%
Price Returns
2W
+18.5%
1M
-49.8%
3M
-63.8%
6M
-79.9%
12M
-38.9%
Technicals
52W High
$13.04
52W Low
$0.97
50d MA
$1.86
200d MA
$5.13
RSI (14)
32.70
ATR (14)
$0.11
Beta
1.00
Avg Volume
495K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 4:08am
· Source: financialmodelingprep.com